Founder and CEO of Brooks Bell Inc.
Executive Partner, Sofinnova Ventures
Senior health advisor for Esri
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
The MIT Enterprise Forum of Cambridge hosts a discussion on drug discovery in neuropharmacology. From the event website: “Disorders of the brain, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease and psychiatric diseases such as schizophrenia and depression, pose some of the hardest challenges for the biopharmaceutical industry. The disease burden from brain disorders is enormous, and the commercial potential is correspondingly attractive to industry and its investors. However, complex pathophysiology, poor preclinical models, a lack of reliable biomarkers and expensive clinical trials all impede development of new therapies. Join us for a discussion of how the biopharmaceutical industry is addressing these challenges, with guest speakers from the cutting edge of neuroscience drug discovery.”
Keynote speaker: Darryle D. Schoepp, Ph.D, Senior Vice President and Franchise Head, Neuroscience,
Merck Research Laboratories.
Company Presentation: FoldRx Pharmaceuticals, Inc., Christoph M. Adams, Ph.D., Chief Business Officer.
Panel moderator: Skip Irving, Partner and Managing Director, Health Advances LLC Panelists: Douglas M. Fambrough, Ph.D., General Partner, Oxford Bioscience Partners; Todd Sherer, Ph.D.
Vice President, Research Programs, The Michael J. Fox Foundation for Parkinson’s Research.
Information and registration here.